Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) saw a substantial increase in the value of its shares today, with stock prices rising 43.55% to $3.62. The increase demonstrates rising investor trust in the transaction’s strategic importance and possible influence on the market.
Strategic Milestone Approval
In a significant move, Scinai Immunotherapeutics disclosed that the Italian government has approved SCNI’s option to purchase 100% of Pincell S.r.l.’s share capital and voting rights under its Golden Power legislation. Scinai Immunotherapeutics may now proceed with closing the purchase as this regulatory permission removes one of the main legal obstacles mentioned in the March 2025 option agreement.
The authorization followed an extensive review by Italy’s Coordination Group for the exercise of special powers, based on findings from the Ministry of Health. The approval also covers licensing arrangements between Pincell and SCNI’s Polish subsidiary, Scinai Immunotherapeutics Sp. Z.O.O, for the use of Pincell’s intellectual property.
Pincell’s Pipeline and Strategic Fit
PC111, a completely human monoclonal antibody that targets the Fas/FasL pathway, is Pincell’s top therapeutic candidate. It is being developed to treat severe autoimmune dermatological disorders such Toxic Epidermal Necrolysis (TEN), Stevens-Johnson Syndrome (SJS), and pemphigus. Notably, PC111 has previously received the European Medicines Agency’s Orphan Drug Designation for Pemphigus, demonstrating its potential as a treatment for uncommon illnesses.
Next Steps and Pending Conditions
While the regulatory clearance is a pivotal achievement, Scinai Immunotherapeutics emphasized that the acquisition remains incomplete. The conclusion of a €12 million grant application made under the European Funds for a Modern Economy (FENG) program to assist PC111’s development is one of the closing requirements the firm is still pursuing. There will likely be a financial decision between mid-July and early August 2025.
Considered a game-changer for its immunotherapeutics portfolio, Scinai Immunotherapeutics (SCNI) reiterated its intention to complete all outstanding commitments necessary to complete the transaction.
